NZ739028A - Humanized or chimeric cd3 antibodies - Google Patents

Humanized or chimeric cd3 antibodies

Info

Publication number
NZ739028A
NZ739028A NZ739028A NZ73902816A NZ739028A NZ 739028 A NZ739028 A NZ 739028A NZ 739028 A NZ739028 A NZ 739028A NZ 73902816 A NZ73902816 A NZ 73902816A NZ 739028 A NZ739028 A NZ 739028A
Authority
NZ
New Zealand
Prior art keywords
antibodies
humanized
chimeric
mutation
treatment
Prior art date
Application number
NZ739028A
Other languages
English (en)
Inventor
Rik Rademaker
Isil Altintas
Patrick Engelberts
Janine Schuurman
Paul Parren
Original Assignee
Genmab As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2016/050296 external-priority patent/WO2016110576A1/en
Application filed by Genmab As filed Critical Genmab As
Priority to NZ778208A priority Critical patent/NZ778208B2/en
Priority to NZ778205A priority patent/NZ778205B2/en
Publication of NZ739028A publication Critical patent/NZ739028A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4216—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-viral Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NZ739028A 2015-07-15 2016-07-14 Humanized or chimeric cd3 antibodies NZ739028A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
NZ778208A NZ778208B2 (en) 2016-07-14 Humanized or chimeric CD3 antibodies
NZ778205A NZ778205B2 (en) 2016-07-14 Humanized or chimeric CD3 antibodies

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA201500413 2015-07-15
DKPA201500414 2015-07-15
DKPA201500416 2015-07-16
PCT/EP2016/050296 WO2016110576A1 (en) 2015-01-08 2016-01-08 Bispecific antibodies against cd3 and cd20
PCT/EP2016/066845 WO2017009442A1 (en) 2015-07-15 2016-07-14 Humanized or chimeric cd3 antibodies

Publications (1)

Publication Number Publication Date
NZ739028A true NZ739028A (en) 2023-05-26

Family

ID=57757079

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ739028A NZ739028A (en) 2015-07-15 2016-07-14 Humanized or chimeric cd3 antibodies

Country Status (14)

Country Link
US (4) US11359015B2 (enExample)
EP (1) EP3322727A1 (enExample)
JP (3) JP2018526981A (enExample)
KR (2) KR20250048113A (enExample)
CN (3) CN108368172B (enExample)
AU (2) AU2016293073B2 (enExample)
BR (1) BR112018000696A2 (enExample)
CA (1) CA2992380A1 (enExample)
EA (1) EA201890305A1 (enExample)
IL (2) IL310467A (enExample)
MX (2) MX395317B (enExample)
NZ (1) NZ739028A (enExample)
UA (1) UA128057C2 (enExample)
WO (1) WO2017009442A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6514103B2 (ja) 2012-07-06 2019-05-15 ゲンマブ ビー．ブイ． 三重変異を有する二量体タンパク質
ES2776706T3 (es) 2013-07-05 2020-07-31 Genmab As Anticuerpos contra CD3 humanizados o quiméricos
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
FI3592769T3 (fi) 2017-03-09 2024-07-30 Genmab As Vasta-aineita PD-L1:tä vastaan
WO2018208877A1 (en) * 2017-05-09 2018-11-15 Yale University Basehit, a high-throughput assay to identify proteins involved in host-microbe interaction
EP3409322A1 (en) 2017-06-01 2018-12-05 F. Hoffmann-La Roche AG Treatment method
WO2018237148A1 (en) 2017-06-21 2018-12-27 Gilead Sciences, Inc. Multispecific antibodies that target hiv gp120 and cd3
AU2019233523A1 (en) 2018-03-12 2020-10-01 Genmab A/S Antibodies
EP3765520A1 (en) * 2018-03-14 2021-01-20 NovImmune SA Anti-cd3 epsilon antibodies and methods of use thereof
JP7759805B2 (ja) * 2018-08-28 2025-10-24 アンブルックス，インコーポレイテッド 抗ｃｄ３抗体葉酸生物複合体およびその使用
EP3973000A4 (en) * 2019-06-07 2023-09-06 Adimab, LLC HIGH AFFINITY ANTI-CD3 ANTIBODIES AND METHOD FOR THE PRODUCTION AND USE THEREOF
CN114901688A (zh) * 2019-07-29 2022-08-12 杜兰教育基金委员会 针对念珠菌的抗体及其用途
EP4028424A1 (en) 2019-09-12 2022-07-20 Genmab A/S Bispecific antibodies binding to 5t4 and cd3 for use in treatment of cancer
CA3168613A1 (en) 2020-03-18 2021-09-23 Genmab A/S Antibodies binding to b7h4
EP4146175A1 (en) 2020-05-08 2023-03-15 Genmab A/S Bispecific antibodies against cd3 and cd20
WO2022053653A1 (en) 2020-09-10 2022-03-17 Genmab A/S Bispecific antibodies against cd3 and cd20 for treating chronic lymphocytic leukemia
CA3192251A1 (en) 2020-09-10 2022-03-17 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
MX2023003749A (es) * 2020-10-02 2023-04-24 Genmab As Anticuerpos capaces de unirse al receptor huerfano 2 similar a tirosina-cinasa receptora (ror2) y anticuerpos biespecificos que se unen a ror2 y al cumulo de diferenciacion 3 (cd3).
JP2024519212A (ja) 2021-05-07 2024-05-09 ジェンマブ エー／エス Ｂ７ｈ４およびｃｄ３に結合する二重特異性抗体を含む薬学的組成物
CN113527493B (zh) * 2021-07-20 2023-10-27 广州爱思迈生物医药科技有限公司 一种b7-h3抗体及其应用
KR20240082397A (ko) * 2021-10-08 2024-06-10 젠맵 에이/에스 Cd30 및 cd3에 결합하는 항체
CN115368446B (zh) * 2022-07-19 2025-08-08 合肥天港免疫药物有限公司 双特异性抗体及其应用
WO2024088987A1 (en) 2022-10-26 2024-05-02 F. Hoffmann-La Roche Ag Combination therapy for the treatment of cancer
AR132290A1 (es) 2023-04-05 2025-06-11 Genmab As Composiciones farmacéuticas que comprenden anticuerpos que se unen a cd30 y cd3

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU751659B2 (en) 1997-05-02 2002-08-22 Genentech Inc. A method for making multispecific antibodies having heteromultimeric and common components
DE10043437A1 (de) 2000-09-04 2002-03-28 Horst Lindhofer Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites
US20100081792A1 (en) 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
AU2003250074B2 (en) 2002-07-18 2010-09-09 Merus N.V. Recombinant production of mixtures of antibodies
US7741568B2 (en) 2005-01-13 2010-06-22 The Wiremold Company Downward facing receptacle assembly for cable raceway
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CA2646965C (en) 2006-03-24 2016-06-21 Jonathan H. Davis Engineered heterodimeric protein domains
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
ES2667863T3 (es) 2007-03-29 2018-05-14 Genmab A/S Anticuerpos biespecíficos y métodos de producción de los mismos
FI2155783T4 (fi) 2007-04-03 2022-12-15 Lajien välisesti spesifinen cd3-epsilon-sitoutumisdomeeni
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
ES2563027T3 (es) 2008-01-07 2016-03-10 Amgen Inc. Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
WO2010015792A1 (en) 2008-08-06 2010-02-11 Argenta Discovery Limited Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors
US8927694B2 (en) 2008-11-18 2015-01-06 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
SG10201407908VA (en) 2008-12-19 2015-01-29 Macrogenics Inc Covalent diabodies and uses thereof
JP2012521768A (ja) 2009-03-27 2012-09-20 ジモジェネティクス・インコーポレイテッド 抗体−受容体の組み合わせを含む多特異的結合性タンパク質を用いるための組成物および方法
EP2424567B1 (en) 2009-04-27 2018-11-21 OncoMed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
KR101224468B1 (ko) 2009-05-20 2013-01-23 주식회사 파멥신 신규한 형태의 이중표적항체 및 그 용도
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
AR080794A1 (es) 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
US9150663B2 (en) 2010-04-20 2015-10-06 Genmab A/S Heterodimeric antibody Fc-containing proteins and methods for production thereof
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
JP5997154B2 (ja) 2010-08-16 2016-09-28 ノビミューン エスアー 多重特異性多価抗体の生成方法
RU2604490C2 (ru) 2010-11-05 2016-12-10 Займворкс Инк. ДИЗАЙН УСТОЙЧИВОГО ГЕТЕРОДИМЕРНОГО АНТИТЕЛА С МУТАЦИЯМИ В Fc ДОМЕНЕ
CN103796677B (zh) * 2011-04-20 2019-08-16 健玛保 针对her2和cd3的双特异性抗体
SG195072A1 (en) 2011-05-21 2013-12-30 Macrogenics Inc Cd3-binding molecules capable of binding to human and non-human cd3
SI2771364T1 (sl) 2011-10-27 2019-10-30 Genmab As Produkcija heterodimernih proteinov
CN120383672A (zh) 2012-04-20 2025-07-29 美勒斯公司 用于产生免疫球蛋白样分子的方法和手段
WO2013186613A1 (en) * 2012-06-14 2013-12-19 Nasvax Ltd. Humanized antibodies to cluster of differentiation 3 (cd3)
EP3786183A3 (en) * 2012-06-15 2021-06-09 Imaginab, Inc. Antigen binding constructs to cd3
DK2869845T3 (da) 2012-07-06 2019-12-09 Genmab Bv Dimert protein med tredobbelte mutationer
JP6514103B2 (ja) 2012-07-06 2019-05-15 ゲンマブ ビー．ブイ． 三重変異を有する二量体タンパク質
WO2014081202A1 (ko) 2012-11-21 2014-05-30 주식회사 파멥신 Vegfr-2와 dll4를 표적으로 하는 이중표적항체 및 이를 포함하는 약학적 조성물
ES2776706T3 (es) * 2013-07-05 2020-07-31 Genmab As Anticuerpos contra CD3 humanizados o quiméricos
WO2016110576A1 (en) 2015-01-08 2016-07-14 Genmab A/S Bispecific antibodies against cd3 and cd20

Also Published As

Publication number Publication date
US20190284278A1 (en) 2019-09-19
AU2016293073A1 (en) 2018-02-01
KR20250048113A (ko) 2025-04-07
US20220389101A1 (en) 2022-12-08
IL256562B2 (en) 2024-07-01
IL310467A (en) 2024-03-01
US20220380464A1 (en) 2022-12-01
JP2025038049A (ja) 2025-03-18
CN108368172B (zh) 2022-06-14
JP2022023862A (ja) 2022-02-08
KR102786353B1 (ko) 2025-03-26
NZ778208A (en) 2025-05-02
AU2016293073B2 (en) 2022-12-22
EA201890305A1 (ru) 2018-07-31
CA2992380A1 (en) 2017-01-19
AU2023201733A1 (en) 2023-07-13
UA128057C2 (uk) 2024-03-27
KR20180030635A (ko) 2018-03-23
BR112018000696A2 (pt) 2018-09-18
MX2018000347A (es) 2018-03-14
CN114989302B (zh) 2025-08-05
IL256562B1 (en) 2024-03-01
EP3322727A1 (en) 2018-05-23
WO2017009442A1 (en) 2017-01-19
NZ778205A (en) 2025-05-02
US11359015B2 (en) 2022-06-14
JP2018526981A (ja) 2018-09-20
US20230027394A1 (en) 2023-01-26
CN114989302A (zh) 2022-09-02
CN108368172A (zh) 2018-08-03
CN120842408A (zh) 2025-10-28
IL256562A (en) 2018-02-28
MX395317B (es) 2025-03-25
MX2022011002A (es) 2022-10-07
JP7604351B2 (ja) 2024-12-23

Similar Documents

Publication Publication Date Title
NZ739028A (en) Humanized or chimeric cd3 antibodies
EP4631978A3 (en) Humanized or chimeric cd3 antibodies
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
PH12018500635A1 (en) Bispecific antibodies specific for pd1 and tim3
ZA201901066B (en) Anti- gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof
MX2018012757A (es) Anticuerpos agonistas que se unen a cd40 humana y usos de los mismos.
IL259082A (en) Anti-il1rap antibodies, bispecific antigen binding molecules that bind il1rap and cd3, and uses thereof
ZA201708265B (en) Tigit-binding agents and uses thereof
SA517381703B1 (ar) C10orf54 - أجسام مضادة لـ واستخداماتها
JOP20190002A1 (ar) أجسام مضادة (أنتي – بي دي – 1) وطريقة الإنتاج وطريقة استخدام كل منهم
SG10201902924RA (en) Antibodies that bind ebola glycoprotein and uses thereof
MX2018010948A (es) INMUNOGLOBULINAS DE ENLACE A TGFß1 Y USOS DE LAS MISMAS.
MX2018000569A (es) Anticuerpos anti-tfr y su uso en el tratamiento de trastornos proliferativos e inflamatorios.
MX2018008934A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso.
SG10201901057UA (en) Anti-pd-l1 antibodies
NZ759835A (en) Cd38 modulating antibody
PH12018500100A1 (en) Antibodies that bind to sortilin and inhibit the binding of progranulin
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof
MX2020002406A (es) Anticuerpo anti-epha4.
PH12019502313A1 (en) Anti-pd-l1-anti-tim-3 bispecific antibodies
MX2018011244A (es) Anticuerpos monoclonales neutralizantes para il-25 y usos de estos.
MA40536A (fr) Anticorps anti-alpha v bêta 5 humanisés et leurs utilisations
MX2016014726A (es) Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1.
MY186726A (en) Anti-activin a antibodies and uses thereof

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 JUL 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20240530

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 JUL 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20250529